Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples

Gynecologic Oncology

Volumn 93, Issue 1, 2004, Pages 98-106

  Penson, Richard T ^a   Oliva, Esther ^b   Skates, Steven J ^a   Glyptis, Tina ^b   Fuller Jr , Arlan F ^a   Goodman, Annekathryn ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; MDR 1; P gp; Taxane

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C219; MONOCLONAL ANTIBODY C494; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROGESTERONE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR RESISTANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 1842477895     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.11.053     Document Type: Article

References (34)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
2. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S.et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9:1991;389-393.
3. Ozols R.F., Vermorken J.B. Chemotherapy of advanced ovarian cancer: current status and future directions. Semin. Oncol. 24(Suppl 2):1997;1-9.
4. Suffness M. Is taxol a surrogate for a universal regulator of mitosis? In vivo. 8:1994;867-878.
5. Gelmon K.A. Biweekly paclitaxel (Taxol) and cisplatin in breast and ovarian cancer. Semin. Oncol. 21:1994;24-28.
6. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T.et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:1997;17118-17125.
7. Haber M., Burkhart C.A., Regl D.L., Madafiglio J., Norris M.D., Horwitz S.B. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. Biol. Chem. 270:1995;31269-31275.
8. Tai Y.T., Lee S., Niloff J., Weisman C., Strobel T., Cannistra S.A. BAX protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol. 16:1998;2583-2590.
9. Duan Z., Penson R.T., Fuller A.F., Seiden M.V. Drug resistance markers in epithelial ovarian carcinoma. CME J. Gynecol. Oncol. 1:1999;69-77.
10. Germann U.A. P-glycoprotein-A mediator of multidrug resistance in tumor cells. Eur. J. Cancer. 32A:1996;927-944.
11. Nooter K., Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract. 192:1996;768-780.
12. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U. S. A. 84:1987;3004-3008.
13. Johnson S.W., Perez R.P., Godwin A.K., Yeung A.T., Handel L.M., Ozols R.F.et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol. 47:1994;689-697.
14. Eck L., Pavich D., Fruehauf J.P. MDR-1 expression by human ovarian tumors is associated with taxol resistance. Proc. Am. Assoc. Cancer Res. 34:1993;232.
15. Chan H.S., Bradley G., Thorner P., Haddad G., Gallie B.L., Ling V. A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines. Lab. Invest. 59:1988;870-875.
16. Liu B., Sun D., Xia W., Hung M.C., Yu D. Cross-reactivity of C219 anti-p170 (md-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J. Natl. Cancer Inst. 89:1997;1524-1529.
17. Georges E., Bradley G., Gariepy J., Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 87:1990;152-156.
18. Rao V.V., Anthony D.C., Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res. 54:1994;1536-1541.
19. Miller A., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
20. Rubin S.C., Finstad C.L., Hoskins W.J., Saigo P.E., Provencher D.M., Federici M.G.et al. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am. J. Obstet. Gynecol. 163:1990;69-73.
21. Hill B.T. Interactions between antitumour agents and radiation and the expression of resistance. Cancer Treat. Rev. 18:1991;149-190.
22. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S.et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 94:1999;1086-1099.
23. Wunder J.S., Bull S.B., Aneliunas V., Lee P.D., Davis A.M., Beauchamp C.P.et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J. Clin. Oncol. 18:2000;2685-2694.
24. Beck W.T., Grogan T.M., Willman C.L., Cordon-Cardo C., Parham D.M., Kuttesch J.F.et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 56:1996;3010-3020.
25. Lacueva F.J., Teruel A., Calpena R., Medrano J., Mayol M.J., Perez-Vazquez M.T.et al. Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies. Histopathology. 32:1998;328-334.
26. Axiotis C.A., Monteagudo C., Merino M.J., LaPorte N., Neumann R.D. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am. J. Pathol. 138:1991;799-806.
27. Abolhoda A., Wilson A.E., Ross H., Danenberg P.V., Burt M., Scotto K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5:1999;3352-3356.
28. Alberts D.S., Taetle R., Frutiger E., Heddens D., Laptalo L., Einspahr J.et al. Multidrug resistance expression as an independent risk factor for poor survival in optimal stage III ovarian cancer. Proc. Am. Soc. Clin. Oncol. 16:1998;1356a.
29. Holzmayer T.A., Hilsenbeck S., Von Hoff D.D., Roninson I.B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst. 84:1992;1486-1491.
30. Kern D.H. Heterogeneity of drug resistance in human breast and ovarian cancers. Cancer J. Sci. Am. 4:1998;41-45.
31. Tewari K.S., Kyshtoobayeva A.S., Mehta R.S., Yu I.R., Burger R.A., DiSaia P.J.et al. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol. Oncol. 78:2000;130-136.
32. Goff B.A., Ries J.A., Els L.P., Coltrera M.D., Gown A.M. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol. Oncol. 70:1998;378-385.
33. van der Zee A.G., Hollema H., Suurmeijer A.J., Krans M., Sluiter W.J., Willemse P.H.et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13(1):1995 (Jan);70-78.
34. van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G.et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med. 332:1995;629-634.